Vobarilizumab: Phase IIb data

Top-line data from a double-blind, international Phase IIb trial in 251 patients with moderately to severely active RA who were intolerant to methotrexate or for whom continued methotrexate treatment was inappropriate showed that 150 mg subcutaneous

Read the full 360 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE